Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Edstrom
Saned Gharari
Eric Davis

Showing results (91-100 of 167) with videos related to

Pageof 17
Sort By:
Cancer Research|June 3, 2005
Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomasLynda Song, Andrei Zlobin, Pushpankur Ghoshal, et al.
Oncotarget|November 16, 2017
Tumor <i>Trp53</i> status and genotype affect the bone marrow microenvironment in acute myeloid leukemiaRodrigo Jacamo, R Eric Davis, Xiaoyang Ling, et al.
Nature Communications|January 27, 2019
FGL2 promotes tumor progression in the CNS by suppressing CD103<sup>+</sup> dendritic cell differentiationJun Yan, Qingnan Zhao, Konrad Gabrusiewicz, et al.
Blood|June 3, 2015
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapyByung-Sik Cho, Zhihong Zeng, Hong Mu, et al.
Frontiers in Oncology|August 31, 2023
Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patientsAlexandre G Troullioud Lucas, Jaap Jan Boelens, Susan E Prockop, et al.
Discover Oncology|June 17, 2024
Targeting IL-11R/EZH2 signaling axis as a therapeutic strategy for osteosarcoma lung metastasesEswaran Devarajan, R Eric Davis, Hannah C Beird, et al.
Blood|April 9, 2013
Prognostic impact and targeting of CRM1 in acute myeloid leukemiaKensuke Kojima, Steven M Kornblau, Vivian Ruvolo, et al.
Journal for Immunotherapy of Cancer|November 25, 2023
Chimeric antigen receptor T cells to target CD79b in B-cell lymphomasFuliang Chu, Jingjing Cao, Jingwei Liu, et al.
Cancer Research|March 2, 2018
Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 InhibitionJo Ishizawa, Kenji Nakamaru, Takahiko Seki, et al.
Journal for Immunotherapy of Cancer|July 30, 2021
Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AMLShelley Herbrich, Natalia Baran, Tianyu Cai, et al.
Pageof 17

Showing results (91-100 of 167) with videos related to

Sort By:
Pageof 17
Cancer Research|June 3, 2005
Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomasLynda Song, Andrei Zlobin, Pushpankur Ghoshal, et al.
Oncotarget|November 16, 2017
Tumor <i>Trp53</i> status and genotype affect the bone marrow microenvironment in acute myeloid leukemiaRodrigo Jacamo, R Eric Davis, Xiaoyang Ling, et al.
Nature Communications|January 27, 2019
FGL2 promotes tumor progression in the CNS by suppressing CD103<sup>+</sup> dendritic cell differentiationJun Yan, Qingnan Zhao, Konrad Gabrusiewicz, et al.
Blood|June 3, 2015
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapyByung-Sik Cho, Zhihong Zeng, Hong Mu, et al.
Frontiers in Oncology|August 31, 2023
Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patientsAlexandre G Troullioud Lucas, Jaap Jan Boelens, Susan E Prockop, et al.
Discover Oncology|June 17, 2024
Targeting IL-11R/EZH2 signaling axis as a therapeutic strategy for osteosarcoma lung metastasesEswaran Devarajan, R Eric Davis, Hannah C Beird, et al.
Blood|April 9, 2013
Prognostic impact and targeting of CRM1 in acute myeloid leukemiaKensuke Kojima, Steven M Kornblau, Vivian Ruvolo, et al.
Journal for Immunotherapy of Cancer|November 25, 2023
Chimeric antigen receptor T cells to target CD79b in B-cell lymphomasFuliang Chu, Jingjing Cao, Jingwei Liu, et al.
Cancer Research|March 2, 2018
Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 InhibitionJo Ishizawa, Kenji Nakamaru, Takahiko Seki, et al.
Journal for Immunotherapy of Cancer|July 30, 2021
Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AMLShelley Herbrich, Natalia Baran, Tianyu Cai, et al.
Pageof 17